Posts by cowic

Sarcomas are rare and complex conditions which make specialized care mandatory. However, due to both the scarcity of expertise and the scattering of small patient populations across the EU, it can be challenging to provide this highly specialized care for all patients.   So-called “European Reference Networks” (ERNs) pool the expertise among EU member states…

  The updated ESMO-EURACAN-GENTURIS (European Society for Medical Oncology; European Reference Network for Rare Adult Solid Cancers; European Reference Network for Genetic Tumour Risk Syndromes) Clinical Practice Guidelines for Soft Tissue and Visceral Sarcomas have been published in Annals of Oncology at 22.7.2021. Please find them here: https://www.annalsofoncology.org/article/S0923-7534(21)02184-0/fulltext

  The updated ESMO-EURACAN-GENTURIS (European Society for Medical Oncology; European Reference Network for Rare Adult Solid Cancers; European Reference Network for Genetic Tumour Risk Syndromes) Clinical Practice Guidelines for Soft Tissue and Visceral Sarcomas have been published in Annals of Oncology at 22.7.2021. Please find them here: https://www.annalsofoncology.org/article/S0923-7534(21)02184-0/fulltext

Project: Desmoid and fertility Who is it for and what is it about? In collaboration with IRCCS NATIONAL TUMOR INSTITUTE FOUNDATION, we are spreading a questionnaire to study the impact of a diagnosis of desmoid tumor on the lives of women during their fertility age. The results of this study will help understand how desmoid…

  Professor Winette van der Graaf, The Netherlands, has been elected as new EORTC President-Elect from 2021-2024 – our heartfelt congratulations to a dedicated and enthusiastic #sarcoma expert!   Read more: https://bit.ly/2TQC8o7

In collaboration with the Fondazione IRCCS Istituto Nazionale dei Tumori, the Desmoid Foundation Italy is launching a survey to study the correlation between desmoid tumors and pregnancy. The results of this study will help to understand how desmoid tumors behave DURING pregnancy with the aim of improving the future of our patients who dream of…

            The winners of the SPAEN Advocacy in Action Award 2020 have been announced! We congratulate them for their fantastic work:– V Care / SPANDAN, India– The Bone Cancer Research Trust, UK– The Polish Sarcoma and Melanoma Group Learn more about the winning projects, about all applications and about the…

SOS Desmoide France will hold its first webconference Saturday, January 30, 2021, from 9:30 to 12:00 AM Paris time. It is free and open for everybody, patients, relatives, physicians. You will have the opportunity to hear respected experts explain how desmoid tumors are treated in France, present the research projects that SOS Desmoid decided to…

End of September, a new therapy option for GIST patients with D842V mutation was approved for the EU: Avapritinib (Ayvakyt®) from Blueprint Medicines is a highly selective tyrosine kinase inhibitor. It is directed against the D842V mutation in exon 18, which has been shown to be resistant to all drugs available to date. The approval…